IHE vs. XBI: Pharma Stability or Biotech Growth — Which Healthcare ETF Is the Better Buy?
Comparing the iShares U.S. Pharmaceuticals ETF (IHE +2.71%) to the State Street SPDR S&P Biotech ETF (XBI +5.90%) illustrates a familiar healthcare trade-off: the relative stability of massive pharmaceutical conglomerates versus the high-volatility growth potential of early stage biotechnology.
Investors looking for healthcare exposure often face a choice between specialized sub-sectors with very different risk profiles. While both of these funds invest in medical innovation, IHE leans on established pharma giants with steady cash flows, while XBI tracks a broader, more volatile slice of the biotech industry that’s highly sensitive to clinical trial results and research breakthroughs.
Snapshot (cost & size)
| Metric | XBI | IHE |
|---|---|---|
| Issuer | State Street | iShares |
| Expense ratio | 0.35% | 0.37% |
| 1-year return (as of Aug. 18, 2026) | 78.28% | 54.23% |
| Dividend yield | 0.39% | 1.44% |
| Beta | 1.14 | 0.50 |
| AUM | $9.6 billion | $1.7 billion |
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-year return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
XBI is the slightly cheaper fund, with a 0.35% expense ratio versus 0.37% for IHE. For income-focused investors, IHE’s dividend yield of 1.44% is more than a full percentage point higher than XBI’s 0.39%.
Performance & risk comparison
| Metric | XBI | IHE |
|---|---|---|
| Max drawdown (5 yr) | (63.89%) | (16.02%) |
| Growth of $1,000 over 5 years (total return) | $1,438 | $1,816 |
XBI has been a standout performer recently, surging more than 78% over the past year — but its runs tend to come with more turbulence. XBI has also weathered a steep 64% maximum drawdown over the past five years, a reminder of just how volatile clinical-stage biotech investing can be. IHE, by contrast, has delivered higher — and steadier — 5-year returns, with far less dramatic peak-to-trough swings.
What’s inside
Launched in 2006, IHE provides targeted exposure to the U.S. pharmaceutical market. Its concentrated portfolio of 56 holdings is dominated by industry leaders, led by Johnson & Johnson (JNJ +0.85%) at 22.1%, Eli Lilly (LLY +4.46%) at 20.8%, and Bristol Myers Squibb (BMY +2.36%) at 4.8%.
XBI takes a different approach, tracking an equal-weighted index of 155 companies. That structure gives smaller firms far more influence than they’d have in a traditional market-cap-weighted fund. Top holdings include Apogee Therapeutics Inc (APGE +0.10%) at 1.7%, Oruka Therapeutics (ORKA -3.00%) at 1.5%, and Dianthus Therapeutics (DNTH -1.59%) at 1.4%. XBI was launched in 2006.
For more guidance on ETF investing, check out the full guide at this link.
Which looks like the better buy
These are two very different ways of investing in healthcare, and the “right” answer really depends on what an investor is trying to accomplish.
IHE’s concentration in mega-cap pharma names — companies with diversified drug portfolios, steady cash flow, and dividends — makes it a more defensive way to stay invested in the sector. That’s typical of pharma-focused funds: they tend to hold up better during market stress because their revenue isn’t tied to any single drug’s success or failure.
XBI’s equal-weight structure is a notable differentiating factor. By giving small and mid-cap biotech companies as much weight as larger ones, the fund amplifies both the upside of a breakthrough and the downside of a failed trial or funding crunch — which helps explain both its superior one-year performance and its far worse five-year maximum drawdown. That volatility isn’t unusual for biotech; it’s the nature of investing in companies whose value often hinges on binary clinical or regulatory outcomes.
For investors who want healthcare exposure without picking single stocks, the choice largely comes down to time horizon and risk tolerance. Income-focused or more conservative investors may prefer IHE’s steadier profile and higher yield, while those comfortable with sharp swings in pursuit of outsize returns may find XBI’s growth potential more appealing.
It’s also worth noting that funds like these are probably best used as a smaller, satellite position layered on top of a set of diversified core holdings — both come with sector concentration risk that a broad market fund doesn’t carry. Newer investors, in particular, may find they already have reasonable healthcare exposure through an S&P 500 index fund and don’t need a specialized pharma or biotech fund unless they have a specific reason to overweight the sector.
